Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind phase 1b/2 dose escalation study of BOS161721 in systemic lupus erythematosus
2018-000305-23Phase 2Completed
- Sponsor
- Boston Pharmaceuticals
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing BOS161721 escalating doses with Control on limited standard of care (2 arms). Started Nov 2018; status: completed.
02
Drugs
avizakimab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2018-000305-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000305-23.